Introduction
Drug Array Plate Design and Layout:
Drug Array targeted genes and pathways:
Array 1: Apoptosis, Cell cycle, Cytoskeleton, DNA damage, HDAC.
Array 2: Kinase signaling pathways (MEK-ERK, MTOR-S6, NF-κB, NRTK, PAK, PI3K-AKT, PRKC),NOTCH and TNFα signaling pathways.
Array 3: Rac GTPases, Retinoic acid X family, RTK, SMO,Protein modifications, Metabolism.
| Drug Array I | Drug Array II | Drug Array III | |||||||||||
| Drug Name | Targets | Pathway | Drug Name | Targets | Pathway | Drug Name | Targets | Pathway | |||||
| 1 | ABT-263 | BCL2, BCL-XL, BCL-W | Apoptosis | 1 | AZ628 | BRAF | MEK-ERK | 1 | QS11 | ARFGAP | Rac GTPases | ||
| 2 | PAC-1 | CASP3 activator | 2 | SP 600125 | JNK1,2,3 | 2 | EHT 1864 | Rac GTPases | |||||
| 3 | Embelin | XIAP | 3 | AZD6244 | MEK1/2 | 3 | ATRA | Retinoic acid and RXR agonist | Retinioic acid X family | ||||
| 4 | ZM-447439 | AURKB | Cell cycle | 4 | GW 441756 | NTRK1 | 4 | Dasatinib | ABL, SRC, KIT, PDGFR | RTK | |||
| 5 | CGP-60474 | CDK1/2/5/7/9 | 5 | BIRB 0796 | p38, JNK2 | 5 | NVP-TAE684 | ALK | |||||
| 6 | PD-0332991 | CDK4/6 | 6 | CCT007093 | PPM1D | 6 | VX-680 | Aurora A/B/C, FLT3, ABL1, JAK2 | |||||
| 7 | JNJ-26854165 | MDM2 | 7 | NSC-87877 | SHP1/2 (PTN6/11) | 7 | LFM-A13 | BTK | |||||
| 8 | BI-2536 | PLK1/2/3 | 8 | Torin 1 | MTOR | MTOR-S6 | 8 | BIBW2992 | EGFR, ERBB2 | ||||
| 9 | Tipifarnib | Farnesyl-transferase (FNTA) | 9 | PF-4708671 | p70 S6KA | 9 | PD-173074 | FGFR1/3 | |||||
| 10 | S-Trityl-L-cysteine | KIF11 | 10 | KIN001-135 | IKKE | NF-KB | 10 | CEP-701 | FLT3, JAK2, NTRK1, RET | ||||
| 11 | SL 0101-1 | RSK, AURKB, PIM3 | 11 | Parthenolide | NFKB1 | 11 | BMS-536924 | IGF1R | |||||
| 12 | PF-562271 | FAK | Cytoskeleton | 12 | BMS-708163 | gamma-secretase | NOTCH | 12 | PF-02341066 | MET, ALK | |||
| 13 | GSK269962A | ROCK1 | 13 | DAPT | g-secretase | 13 | WH-4-023 | SRC family, ABL | |||||
| 14 | Docetaxel | Microtubules | 14 | GNF-2 | BCR-ABL | NRTK | 14 | BAY 61-3606 | SYK | ||||
| 15 | KU-55933 | ATM | DNA Damage | 15 | BMX-IN-1 | BMX | 15 | Pazopanib | VEGFR, PDGFRA, PDGFRB, KIT | ||||
| 16 | AZD7762 | CHK1/2 | 16 | BMS-509744 | ITK | 16 | Cyclopamine | SMO | SMO | ||||
| 17 | ABT-888 | PARP1/2 | 17 | IPA-3 | PAK | PAK | 17 | Elesclomol | HSP70 | Protein modification | |||
| 18 | Camptothecin | TOP1 | 18 | A-443654 | AKT1/2/3 | PI3K-AKT | 18 | 17-AAG | HSP90 | ||||
| 19 | Etoposide | TOP2 | 19 | OSU-03012 | PDK1 (PDPK1) | 19 | Bortezomib | Proteasome | |||||
| 20 | NU-7441 | DNAPK | 20 | NVP-BEZ235 | PI3K (Class 1) and mTORC1/2 | 20 | DMOG | Prolyl-4-Hydroxylase | |||||
| 21 | Salubrinal | GADD34-PP1C phosphatase | 21 | Staurosporine | PRKC | PRKC | 21 | AICAR | AMPK agonist | Metabolism | |||
| 22 | Vorinostat | HDAC inhibitor Class I, IIa, IIb, IV | HDAC inhibitor | 22 | Lenalidomide | TNF alpha | TNF alpha | 22 | Methotrexate | Dihydrofolate reductase (DHFR) | |||
| 23 | DMSO (with cells) | - | (Control) | 23 | DMSO (with cells) | - | (Control) | 23 | DMSO (with cells) | - | (Control) | ||
| 24 | DMSO (without cells) | - | 24 | DMSO (without cells) | - | 24 | DMSO (without cells) | - | |||||